You are hereFebruary 22, 2018
What’s the Stem Cells Buzz this Week? - iPSC Quality Control, MSCs for Kidney Repair, Endometriosis-derived MSCs, and Stem Cell Protection of Brain Damage!
The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!
Quality Control in iPSC Genomic Integrity Analysis
Reprogramming and extended in vitro culture can promote the accumulation of genomic abnormalities in induced pluripotent stem cells (iPSCs), leading to a need for the careful monitoring of genomic stability. Now, a new STEM CELLS article from the lab of John De Vos (Univ. Montpellier, France) reviews the “quality control” of iPSCs; how to classify these abnormalities, the tools for their detection, and the quality metrics employed for decision-making in a research and clinical setting. Assou et al. also report simple recommendations for the minimum genome integrity checks when working with any type of pluripotent stem cells.
Targeting MSCs to the Ischemic Kidney
New research from the labs of Xiangyang Zhu and Lilach O. Lerman (Mayo Clinic, Rochester, Minnesota, USA) recently assessed how coating with an antibody (ab) specific for an injured-kidney specific antigen (KIM1) might boost mesenchymal stem cell (MSC) homing, grafting, and kidney repair. Their STEM CELLS Translational Medicine study discovered that KIM1-ab-coated MSCs exhibited selective homing and greater kidney retention following systemic administration into a mouse model, which led to improved renal perfusion and capillary density and attenuated oxidative damage, apoptosis, and fibrosis. Zou et al. suggest that this novel method might be useful to selectively target injured kidneys and supports further development of strategies to enhance cell-based treatment of kidney injury.
Endometriosis-derived MSCs: A new Target?
An exciting new study from the lab of Hugh S. Taylor (Yale School of Medicine, New Haven, CT, USA) recently set out to discover if cells derived from endometriosis, the ectopic growth of endometrial tissue, can enter the circulation and propagate in a mouse model. Their new STEM CELLS study now established that endometriosis-derived mesenchymal stem cells (MSCs) enter the circulation in response to CXCL12 to disseminate the disease. Therefore, Li et al. highlight endometriosis MSCs as potential targets for endometriosis therapies.
MSCs Protect from Brain Damage
Recent research from the groups of Dezhi Mu and Yi Qu (Sichuan University, Chengdu, Sichuan, China) has centered on the application of mesenchymal stem cells (MSCs) as protective agents for the treatment of brain damage. Their new STEM CELLS study discovered that MSC treatment following hypoxic-ischemic injury increased BDNF expression and reduced mTOR pathway activation, resulting in increased autophagy and enhanced neuroprotection. Zheng et al. hope that their research may provide the impetus for the exploration of new strategies for treating neonates with similar brain injuries.
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!